Direct interferon-γ-mediated protection caused by a recombinant coxsackievirus B3

Virology

Volumn 315, Issue 2, 2003, Pages 335-344

  Henke, Andreas ^a   Zell, Roland ^a   Martin, Ulrike ^a   Stelzner, Axel ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Interferon ; Myocarditis; Protection; Recombinant coxsackievirus; Therapy

Indexed keywords

CYTOKINE; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; COXSACKIE VIRUS B3; CYTOKINE PRODUCTION; CYTOPATHOGENIC EFFECT; HEART PROTECTION; INOCULATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE DEGENERATION; VIRUS INFECTION; VIRUS LOAD; VIRUS MYOCARDITIS; VIRUS RECOMBINANT; VIRUS REPLICATION;

COXSACKIEVIRUS;

EID: 0142185270     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00538-5     Document Type: Article

References (60)

1. Andino R., Silvera D., Suggett S.D., Achacoso P.L., Miller C.J., Baltimore D., Feinberg M.B. Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science. 265:1994;1448-1451.
2. Baboonian C., Davies M.J., Booth J.C., McKenna W.J. Coxsackie B viruses and human heart disease. Curr. Top. Microbiol. Immunol. 223:1997;31-52.
3. Badorff C., Fichtlscherer B., Muelsch A., Zeiher A.M., Dimmeler S. Selective delivery of nitric oxide to a cellular target a pseudosubstrate- coupled dinitrosyl-iron complex inhibits the enteroviral protease 2A . Nitric Oxide. 6:2002;305-312.
4. Badorff C., Fichtlscherer B., Rhoads R.E., Zeiher A.M., Muelsch A., Dimmeler S., Knowlton K.U. Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation a protective mechanism against enteroviral cardiomyopathy . Circulation. 102:2000;2276-2281.
5. Bevan A.L., Zhang H., Li Y., Archard L.C. Nitric oxide and Coxsackievirus B3 myocarditis differential expression of inducible nitric oxide synthase in mouse heart after infection with virulent or attenuated virus . J. Med. Virol. 64:2001;175-182.
6. Billiau A. Interferon-gamma biology and role in pathogenesis . Adv. Immunol. 62:1996;61-130.
7. Bot A., Bot S., Bona C.A. Protective role of gamma interferon during the recall response to influenza virus. J. Virol. 72:1998;6637-6645.
8. Bowles N.E., Richardson P.J., Olsen E.G., Archard L.C. Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet. 1:1986;1120-1123.
9. Chapman N.M., Kim K.S., Tracy S., Jackson J., Hofling K., Leser J.S., Malone J., Kolbeck P. Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice. J. Virol. 74:2000;7952-7962.
10. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
11. Chow L.H., Beisel K.W., McManus B.M. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab. Invest. 66:1992;24-31.
12. Chow L.H., Gauntt C.J., McManus B.M. Differential effects of myocarditic variants of Coxsackievirus B3 in inbred mice. A pathologic characterization of heart tissue damage. Lab. Invest. 64:1991;55-64.
13. Clements G.B., Galbraith D.N., Taylor K.W. Coxsackie B virus infection and onset of childhood diabetes. Lancet. 346:1995;221-223.
14. Curiel R.E., Mason K.M., Dryden T.D., Maurer M.J., Bigley N.J. Cytokines produced early in picornavirus infection reflect resistance or susceptibility to disease. J. Interferon Cytokine Res. 18:1998;587-596.
15. Dalton D.K., Pitts-Meek S., Keshav S., Figari I.S., Bradley A., Stewart T.A. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 259:1993;1739-1742.
16. Feuer R., Mena I., Pagarigan R., Slifka M.K., Whitton J.L. Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J. Virol. 76:2002;4430-4440.
17. Flodstrom M., Horwitz M.S., Maday A., Balakrishna D., Rodriguez E., Sarvetnick N. A critical role for inducible nitric oxide synthase in host survival following coxsackievirus B4 infection. Virology. 281:2001;205-215.
18. Fohlman J., Pauksen K., Morein B., Bjare U., Ilback N.G., Friman G. High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand. J. Infect. Dis. Suppl. 88:1993;103-108.
19. Freedman A.S., Freeman G.J., Rhynhart K., Nadler L.M. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes a potential mechanism for amplification of T cell activation through the CD28 pathway . Cell Immunol. 137:1991;429-437.
20. Geginat G., Ruppert T., Hengel H., Holtappels R., Koszinowski U.H. IFN-gamma is a prerequisite for optimal antigen processing of viral peptides in vivo. J. Immunol. 158:1997;3303-3310.
21. Glück B., Merkle I., Dornberger G., Stelzner A. Expression of inducible nitric oxide synthase in experimental viral myocarditis. Herz. 25:2000;255-260.
22. Grist N.R., Bell E.J., Assaad F. Enteroviruses in human disease. Prog. Med. Virol. 24:1978;114-157.
23. Harris N., Buller R.M., Karupiah G. Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J. Virol. 69:1995;910-915.
24. Heim A., Stille-Siegener M., Pring-Akerblom P., Grumbach I., Brehm C., Kreuzer H., Figulla H.R. Recombinant interferons beta and gamma have a higher antiviral activity than interferon-alpha in coxsackievirus B3-infected carrier state cultures of human myocardial fibroblasts. J. Interferon Cytokine Res. 16:1996;283-287.
25. Henke A., Huber S., Stelzner A., Whitton J.L. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J. Virol. 69:1995;6720-6728.
26. Henke A., Launhardt H., Klement K., Stelzner A., Zell R., Munder T. Apoptosis in coxsackievirus B3-caused diseases interaction between the capsid protein VP2 and the proapoptotic protein siva . J. Virol. 74:(9):2000;4284-4290.
27. Henke A., Wagner E., Whitton J.L., Zell R., Stelzner A. Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization. J. Virol. 72:1998;8327-8331.
28. Henke A., Zell R., Ehrlich G., Stelzner A. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis. J. Virol. 75:2001;8187-8194.
29. Henke A., Zell R., Stelzner A. DNA vaccine-mediated immune responses in Coxsackie virus B3-infected mice. Antiviral Res. 49:2001;49-54.
30. Henry Y., Lepoivre M., Drapier J.C., Ducrocq C., Boucher J.L., Guissani A. EPR characterization of molecular targets for NO in mammalian cells and organelles. FASEB J. 7:1993;1124-1134.
31. Hofling K., Tracy S., Chapman N., Kim K.S., Smith Leser J. Expression of an antigenic adenovirus epitope in a group B coxsackievirus. J. Virol. 74:2000;4570-4578.
32. Horwitz M.S., Krahl T., Fine C., Lee J., Sarvetnick N. Protection from lethal coxsackievirus-induced pancreatitis by expression of gamma interferon. J. Virol. 73:1999;1756-1766.
33. Horwitz M.S., La Cava A., Fine C., Rodriguez E., Ilic A., Sarvetnick N. Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat. Med. 6:2000;693-697.
34. Huber S.A. Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice. Lab. Invest. 76:1997;691-701.
35. Huber S.A., Pfaeffle B. Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J. Virol. 68:1994;5126-5132.
36. Jenkins D.E., Redman R.L., Lam E.M., Liu C., Lin I., Arvin A.M. Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus. J. Infect. Dis. 178:1998;940-948.
37. Kandolf R., Ameis D., Kirschner P., Canu A., Hofschneider P.H. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization an approach to the diagnosis of viral heart disease . Proc. Natl. Acad. Sci. USA. 84:1987;6272-6276.
38. Karupiah G., Xie Q.W., Buller R.M., Nathan C., Duarte C., MacMicking J.D. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science. 261:1993;1445-1448.
39. Knowlton K.U., Badorff C. The immune system in viral myocarditis maintaining the balance . Circ. Res. 85:1999;559-561.
40. Knowlton K.U., Jeon E.S., Berkley N., Wessely R., Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 70:1996;7811-7818.
41. Leipner C., Borchers M., Merkle I., Stelzner A. Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice. J. Hum. Virol. 2:1999;102-114.
42. Lindberg A.M., Crowell R.L., Zell R., Kandolf R., Pettersson U. Mapping of the RD phenotype of the Nancy strain of coxsackievirus B3. Virus Res. 24:1992;187-196.
43. Lindenmann J. From interference to interferon a brief historical introduction . Philos. Trans. R. Soc. Lond. B Biol. Sci. 299:1982;3-6.
44. Liu Y., Janeway C.A. Jr. Interferon gamma plays a critical role in induced cell death of effector T cell a possible third mechanism of self-tolerance . J. Exp. Med. 172:1990;1735-1739.
45. Lowenstein C.J., Hill S.L., Lafond-Walker A., Wu J., Allen G., Landavere M., Rose N.R., Herskowitz A. Nitric oxide inhibits viral replication in murine myocarditis. J. Clin. Invest. 97:1996;1837-1843.
46. Mena I., Perry C.M., Harkins S., Rodriguez F., Gebhard J., Whitton J.L. The role of B lymphocytes in coxsackievirus B3 infection. Am. J. Pathol. 155:1999;1205-1215.
47. Mikami S., Kawashima S., Kanazawa K., Hirata K., Katayama Y., Hotta H., Hayashi Y., Ito H., Yokoyama M. Expression of nitric oxide synthase in a murine model of viral myocarditis induced by coxsackievirus B3. Biochem. Biophys. Res. Commun. 220:1996;983-989.
48. Natarajan P., Johnson J.E. Molecular packing in virus crystals geometry, chemistry, and biology . J. Struct. Biol. 121:1998;295-305.
49. Reimann B.Y., Zell R., Kandolf R. Mapping of a neutralizing antigenic site of Coxsackievirus B4 by construction of an antigen chimera. J. Virol. 65:1991;3475-3480.
50. Saura M., Zaragoza C., McMillan A., Quick R.A., Hohenadl C., Lowenstein J.M., Lowenstein C.J. An antiviral mechanism of nitric oxide inhibition of a viral protase . Immunity. 10:1999;21-28.
51. See D.M., Tilles J.G. Occurrence of coxsackievirus hepatitis in baby rabbits and protection by a formalin-inactivated polyvalent vaccine. Proc. Soc. Exp. Biol. Med. 216:1997;52-56.
52. Slifka M.K., Pagarigan R., Mena I., Feuer R., Whitton J.L. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J. Virol. 75:2001;2377-2387.
53. Tang S., van Rij R., Silvera D., Andino R. Toward a poliovirus-based simian immunodeficiency virus vaccine correlation between genetic stability and immunogenicity . J. Virol. 71:1997;7841-7850.
54. Taub D.D., Lloyd A.R., Conlon K., Wang J.M., Ortaldo J.R., Harada A., Matsushima K., Kelvin D.J., Oppenheim J.J. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J. Exp. Med. 177:1993;1809-1814.
55. Taylor L.A., Carthy C.M., Yang D., Saad K., Wong D., Schreiner G., Stanton L.W., McManus B.M. Host gene regulation during coxsackievirus B3 infection in mice assessment by microarrays . Circ. Res. 87:2000;328-334.
56. Wolfgram L.J., Beisel K.W., Herskowitz A., Rose N.R. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice. J. Immunol. 136:1986;1846-1852.
57. Yang D., Yu J., Luo Z., Carthy C.M., Wilson J.E., Liu Z., McManus B.M. Viral myocarditis identification of five differentially expressed genes in coxsackievirus B3-infected mouse heart . Circ. Res. 84:1999;704-712.
58. Zaragoza C., Ocampo C.J., Saura M., Bao C., Leppo M., Lafond-Walker A., Thiemann D.R., Hruban R., Lowenstein C.J. Inducible nitric oxide synthase protection against coxsackievirus pancreatitis. J. Immunol. 163:1999;5497-5504.
59. Zaragoza C., Ocampo C., Saura M., Leppo M., Wei X.Q., Quick R., Moncada S., Liew F.Y., Lowenstein C.J. The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis. Proc. Natl. Acad. Sci. USA. 95:1998;2469-2474.
60. Zaragoza C., Ocampo C.J., Saura M., McMillan A., Lowenstein C.J. Nitric oxide inhibition of coxsackievirus replication in vitro. J. Clin. Invest. 100:1997;1760-1767.